Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Aβ42 (salivary)

Method of Measurement (Pre-analytical Tools)
Other bodily fluids
Biomarker Measured
Amyloid
Use
Diagnostic
Prognostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Measure salivary levels of amyloid-β protein terminating at position 42 (Aβ42). Large brain deposit of this peptide is a characteristic of AD, and this peptide has been found to be produced by peripheral organs, making it easier to measure using saliva. May be a promising method for noninvasive detection AD during its critical early stages.

Target Population/ Population Being Studied

Patients with mild to moderate AD

Number of Trial Participants

Experiment 1: 7 AD subjects and 4 controls (2017); Experiment 2: 15 patients with mild to moderate AD and 8 healthy controls (2018)

Estimated Trial Completion
completed (not sure what is currently going on
What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)

Sponsor

Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center; Cleveland Clinic Lou Ruvo Center for Brain Health (cited Aurin Biotech Inc as original dectors)

  1. Lee, M., Guo, J. P., Kennedy, K., McGeer, E. G., & McGeer, P. L. (2017). A method for diagnosing Alzheimer’s disease based on salivary amyloid-β protein 42 levels. Journal of Alzheimer's Disease, 55(3), 1175-1182. https://www.ncbi.nlm.nih.gov/pubmed/27792013

  2. Sabbagh, M. N., Shi, J., Arnold, L., & McGeer, P. (2017). SALIVARY AMYLOID-BETA PROTEIN LEVELS CAN DIAGNOSE ALZHEIMER DISEASE AND PREDICT ITS FUTURE ONSET. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 13(7), P710-P711. https://www.ncbi.nlm.nih.gov/pubmed/30257642

  3. Sabbagh, M. N., Shi, J., Lee, M., Arnold, L., Al-Hasan, Y., Heim, J., & McGeer, P. (2018). Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer’s disease dementia from normal controls: preliminary findings. BMC Neurology, 18(1), 155. https://www.ncbi.nlm.nih.gov/pubmed/30257642